Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, was found to downregulate RAD51 in lung cancer cells and sensitize them to mitomycin C [33] and gemcitabine [34]. The gene discussed is RAD51; the disease is lung cancer.